$LBIO breakout. Pr. $8.65 Head & Shoulders chart
Post# of 40
Posted On: 06/05/2016 3:11:00 PM
$LBIO breakout. Pr. $8.65
Head & Shoulders chart
[$$] Frazier, OrbiMed Join $100M Financing for Lion Biotechnologies
at The Wall Street Journal(Fri, Jun 3)
Shares Outstanding: 48.57M
Float: 34.93M
% Held by Insiders: 12.96%
% Held by Institutions: 77.80%
Shares Short (as of May 13, 2016): 5.91M
Short Ratio (as of May 13, 2016): 28.14
Short % of Float (as of May 13, 2016): 15.07%
Headlines
Shares Short (prior month): 5.96M
Lion Biotechnologies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The companys lead product candidate is LN-144, an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) that is in Phase II clinical trial, which are T cells derived from patients tumors for the treatment of patients with refractory metastatic melanoma. It is also developing LN-145 to treat cervical and head and neck cancers. The company has a patent license agreement with the National Institutes of Health to develop, manufacture, and commercialize TIL therapies for the treatment of cervical, head and neck, bladder, lung, ovarian cancer, breast cancer, and colorectal cancers, as well as melanoma; cooperative research and development agreement with the National Institutes of Health and the National Cancer Institute to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patients tumor infiltrating lymphocytes; and manufacturing services agreement with Lonza Walkersville, Inc. and WuXi Apptech to manufacture, package, ship, and handle quality assurance and quality control of clinical trials for TIL products. The company was formerly known as Genesis Biopharma Inc. and changed its name to Lion Biotechnologies, Inc. in September 2013. Lion Biotechnologies, Inc. was founded in 2007 and is based in New York, New York.
Head & Shoulders chart
[$$] Frazier, OrbiMed Join $100M Financing for Lion Biotechnologies
at The Wall Street Journal(Fri, Jun 3)
Shares Outstanding: 48.57M
Float: 34.93M
% Held by Insiders: 12.96%
% Held by Institutions: 77.80%
Shares Short (as of May 13, 2016): 5.91M
Short Ratio (as of May 13, 2016): 28.14
Short % of Float (as of May 13, 2016): 15.07%
Headlines
Shares Short (prior month): 5.96M
Lion Biotechnologies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The companys lead product candidate is LN-144, an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) that is in Phase II clinical trial, which are T cells derived from patients tumors for the treatment of patients with refractory metastatic melanoma. It is also developing LN-145 to treat cervical and head and neck cancers. The company has a patent license agreement with the National Institutes of Health to develop, manufacture, and commercialize TIL therapies for the treatment of cervical, head and neck, bladder, lung, ovarian cancer, breast cancer, and colorectal cancers, as well as melanoma; cooperative research and development agreement with the National Institutes of Health and the National Cancer Institute to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patients tumor infiltrating lymphocytes; and manufacturing services agreement with Lonza Walkersville, Inc. and WuXi Apptech to manufacture, package, ship, and handle quality assurance and quality control of clinical trials for TIL products. The company was formerly known as Genesis Biopharma Inc. and changed its name to Lion Biotechnologies, Inc. in September 2013. Lion Biotechnologies, Inc. was founded in 2007 and is based in New York, New York.
(0)
(0)